Want to see AU:MYX full AI Analyst Report?
Total Valuation
Mayne Pharma Group has a market cap or net worth of AU$230.11M. The enterprise value is AU$224.67.
Market CapAU$230.11M
Enterprise ValueAU$224.67
Share Statistics
Mayne Pharma Group has 81,890,884 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding81,890,884
Owned by Insiders0.31%
Owned by Institutions<0.01%
Financial Efficiency
Mayne Pharma Group’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is -4.33%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)-4.33%
Return on Capital Employed (ROCE)-0.05
Revenue Per Employee1.06M
Profits Per Employee85.94K
Employee Count363
Asset Turnover0.42
Inventory Turnover3.45
Valuation Ratios
The current PE Ratio of Mayne Pharma Group is 9.1. Mayne Pharma Group’s PEG ratio is -0.07.
PE Ratio9.1
PS Ratio0.58
PB Ratio0.57
Price to Fair Value0.57
Price to FCF17.60
Price to Operating Cash Flow14.67
PEG Ratio-0.07
Income Statement
In the last 12 months, Mayne Pharma Group had revenue of 383.68M and earned 24.47M in profits. Earnings per share was 0.31.
Revenue383.68M
Gross Profit192.21M
Operating Income-34.28M
Pretax Income35.76M
Net Income24.47M
EBITDA29.40M
Earnings Per Share (EPS)0.31
Cash Flow
In the last 12 months, operating cash flow was 15.62M and capital expenditures -2.94M, giving a free cash flow of 12.67M billion.
Operating Cash Flow15.62M
Free Cash Flow12.67M
Free Cash Flow per Share0.15
Dividends & Yields
Mayne Pharma Group pays an annual dividend of AU$0.544, resulting in a dividend yield of 12.09%
Dividend Per ShareAU$0.544
Dividend Yield12.09%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.37
52-Week Price Change-45.12%
50-Day Moving Average3.02
200-Day Moving Average2.73
Relative Strength Index (RSI)37.70
Average Volume (3m)230.00K
Important Dates
Mayne Pharma Group upcoming earnings date is Feb 24, 2027, TBA (Confirmed).
Last Earnings DateAug 26, 2026
Next Earnings DateFeb 24, 2027
Ex-Dividend Date―
Financial Position
Mayne Pharma Group as a current ratio of 1.31, with Debt / Equity ratio of 11.05%
Current Ratio1.31
Quick Ratio1.09
Debt to Market Cap0.19
Net Debt to EBITDA-1.33
Interest Coverage Ratio-6.46
Taxes
In the past 12 months, Mayne Pharma Group has paid 4.56M in taxes.
Income Tax4.56M
Effective Tax Rate0.13
Enterprise Valuation
Mayne Pharma Group EV to EBITDA ratio is 6.26, with an EV/FCF ratio of 14.52.
EV to Sales0.48
EV to EBITDA6.26
EV to Free Cash Flow14.52
EV to Operating Cash Flow11.78
Balance Sheet
Mayne Pharma Group has AU$82.25M in cash and marketable securities with AU$43.20M in debt, giving a net cash position of AU$39.05M billion.
Cash & Marketable SecuritiesAU$82.25M
Total DebtAU$43.20M
Net CashAU$39.05M
Net Cash Per ShareAU$0.48
Tangible Book Value Per Share-AU$0.90
Margins
Gross margin is 49.62%, with operating margin of -8.94%, and net profit margin of 6.38%.
Gross Margin49.62%
Operating Margin-8.94%
Pretax Margin9.32%
Net Profit Margin6.38%
EBITDA Margin7.66%
EBIT Margin-8.94%
Analyst Forecast
The average price target for Mayne Pharma Group is AU$3.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetAU$3.75
Price Target Upside17.19% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-5.98%
EPS Growth Forecast―